Is tepotinib officially included in China’s medical insurance system?

Tepotinib is a targeted therapy for patients with MET-mutated non-small cell lung cancer (NSCLC), which has gradually attracted attention in recent years. Tepotinib has been officially launched in China and has been included in China's medical insurance system, providing patients who need this drug with a more convenient way to purchase the drug. This means that eligible patients can obtain reimbursement for part of their drug costs through medical insurance, thereby reducing the burden of treatment. Specific medical insurance reimbursement policies and amounts may vary by region and hospital. Patients need to consult the local hospital pharmacy or medical insurance department for detailed information.

The launch of tepotinib in China provides an important treatment option for patients with MET-mutant non-small cell lung cancer. This drug can effectively control the growth of cancer cells by targeting the MET receptor signaling pathway and has shown good therapeutic effects in clinical studies. After being included in the medical insurance system, patients can enjoy a certain proportion of drug cost reimbursement through medical insurance, which undoubtedly provides substantial help to patients with limited economic conditions. When purchasing drugs, patients can consult their doctor or pharmacy to learn about specific medical insurance reimbursement policies and procedures.

Tepotinib’s original drug in China is relatively expensive, with the price of each box being approximately more than 30,000 yuan. Although the price of the drug is relatively high, because it is included in medical insurance, patients can be partially reimbursed through medical insurance, reducing the burden of treatment costs. The medical insurance policies of different regions and hospitals are different, so patients should specifically understand the relevant policies of local hospitals to ensure that they can smoothly enjoy medical insurance reimbursement. The coverage of medical insurance makes the use of tepotinib more popular and helps more patients obtain treatment with this drug.
In addition to domestic original drugs, patients can also choose to purchase generic drugs in overseas markets. The prices of generic tepotinib drugs produced by Lao Lucius and Lao Daxiong companies are significantly lower than those of the original drugs. Recently, the prices of these generic drugs have been significantly reduced, and the price is about more than 6,000 yuan, which is much lower than the price of the original drugs. The ingredients of generic drugs are basically the same as those of original drugs, and their effects can also meet the treatment needs, making them a viable option for patients with limited economic conditions.
Reference: https://www.tepotinib.com/